RemeGen Co. Ltd. (REGMF)
Company Description
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.
Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases.
RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

Country | CN |
IPO Date | Jan 21, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2,999 |
CEO | Dr. Jianmin Fang |
Contact Details
Address: 58 Middle Beijing Road Yantai, CN | |
Website | https://www.remegen.com |
Stock Details
Ticker Symbol | REGMF |
Exchange | PNK |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | n/a |
CUSIP Number | n/a |
ISIN Number | CNE1000048G6 |
Employer ID | - |
SIC Code | n/a |
Key Executives
Name | Position |
---|---|
Dr. Jianmin Fang | Co-Founder, Chief Executive Officer, GM, Member of Scientific Advisory Board & Executive Director |
Kaisheng Huang | Chief Operating Officer |
Shaojing Tong | Chief Financial Officer & Joint Company Secretary |
Dr. Marie Zhu | Chief Technical Officer |
Dr. Xiaoming Yang Ph.D. | Chief Manufacturing Officer |
Dr. Zhulun Wang | Chief Scientific Officer |
Jian Lin | Executive Director |
Qingkai Wen | Executive Director & Board Secretary |
Weidong Wang | Co-Founder & Executive Chairman |